The Archive · 4 posts
Unlock medical breakthroughs with hVIVO (HVO) on LSE! 🧬 Advancing scientific discovery through clinical trials & innovative solutions. 🚀
hVIVO's 2025 results reveal a strategic reset: diversifying beyond challenge trials into a broader clinical platform, despite a tough year of revenue and margin pressure.
April 15, 2026
Showing 3 of 4 posts
hVIVO reports H1 revenue dip to £24.2M but upgrades full-year EBITDA outlook. Diversification push via CRS & Cryostore acquisitions shows early progress amid sector headwinds.
JoshuaJuly 22, 2025
hVIVO faces contract cancellations amid biotech funding woes but reports record sales pipeline & £47m secured FY25 revenue, highlighting resilience.
JoshuaMay 30, 2025
hVIVO posts record £62.7m revenue & 25.9% EBITDA growth, expands via CRS and Cryostore acquisitions. Targets £73m in 2025, £100m by 2028.
JoshuaApril 10, 2025
April 10, 2025